LORATADINE TABLETS

The Defense Logistics Agency awarded a delivery order under contract SPE2DX-25-D-9900 to DMS PHARMACEUTICAL GROUP INC, with CAGE code 1UNB0, for the supply of 7,000 packages of LORATADINE TABLETS identified by NSN 6505013770448 and NDC 00904-7511-61. The total contract price is $140.07, with a firm-fixed unit price of $20.0100 per package and no variance allowed in quantity. The order was issued on July 14, 2026, and requires delivery by July 29, 2026, to Fort Bragg, North Carolina, under FOB destination terms with the contractor responsible for all transportation costs. The awardee is certified as a small business and a Women-Owned Small Business, affirming eligibility under relevant federal socioeconomic programs. Shipment must avoid parcel post and be sent by the fastest traceable method, with all packaging marked using the Transportation Control Number W91KBP60890104 and the designated NDC. Inspection and acceptance occur at the destination, with government responsibility for verifying conformity to contract requirements. Payment will be processed through the Defense Finance and Accounting Service in Columbus, Ohio, using the accounting code BX: 97X4930 5CBX 001 2620 S33189, with administrative oversight managed by the DLA Troop Support Medical Supply Chain in Philadelphia. The contracting officer is Lisa Quinn, and Shairy M. Cartagena serves as the administrative contact. No standard FAR or DFARS clauses are explicitly included in the delivery order documentation, and no attachments, special requirements, evaluation factors, or contract administration roles beyond the ordering officer and administrative contact are specified. The procurement appears to be a streamlined commercial item purchase under the base IDIQ contract, with minimal clause incorporation and no reference to MIL-STDs, packaging standards, or technical specifications beyond the NSN and NDC. Invoicing and payment procedures reference voucher codes and document identifiers without specifying electronic systems such as WAWF. The order lacks option periods, key personnel provisions, security clearance requirements, or conflict of interest clauses. The absence of clauses, attachments, and detailed evaluation criteria suggests a low-value, routine acquisition with reliance on the